vs
AMERICAN SHARED HOSPITAL SERVICES（AMS）与BioNexus Gene Lab Corp（BGLC）财务数据对比。点击上方公司名可切换其他公司
AMERICAN SHARED HOSPITAL SERVICES的季度营收约是BioNexus Gene Lab Corp的16.0倍（$7.7M vs $483.8K）。AMERICAN SHARED HOSPITAL SERVICES净利率更高（-8.2% vs -214.2%，领先206.0%）。AMERICAN SHARED HOSPITAL SERVICES同比增速更快（-14.8% vs -80.8%）。BioNexus Gene Lab Corp自由现金流更多（$960.1K vs $-2.7M）。过去两年AMERICAN SHARED HOSPITAL SERVICES的营收复合增速更高（21.7% vs -54.9%）
美国共享医院服务公司为医疗机构提供放射治疗、立体定向放射外科及诊断成像设备的整体外包解决方案，免除医院高昂的前期资本投入，主要业务覆盖北美，同时服务拉美及部分亚太地区的公立、私立医院客户。
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
AMS vs BGLC — 直观对比
营收规模更大
AMS
是对方的16.0倍
$483.8K
营收增速更快
AMS
高出66.0%
-80.8%
净利率更高
AMS
高出206.0%
-214.2%
自由现金流更多
BGLC
多$3.6M
$-2.7M
两年增速更快
AMS
近两年复合增速
-54.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.7M | $483.8K |
| 净利润 | $-631.0K | $-1.0M |
| 毛利率 | 11.7% | -0.8% |
| 营业利润率 | -18.1% | -213.5% |
| 净利率 | -8.2% | -214.2% |
| 营收同比 | -14.8% | -80.8% |
| 净利润同比 | 52.5% | -197.5% |
| 每股收益（稀释后） | $-0.09 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSBGLC
| Q4 25 | $7.7M | $483.8K | ||
| Q3 25 | $7.2M | $2.5M | ||
| Q2 25 | $7.1M | $2.3M | ||
| Q1 25 | $6.1M | $2.1M | ||
| Q4 24 | $9.1M | $2.5M | ||
| Q3 24 | $7.0M | $2.6M | ||
| Q2 24 | $7.1M | $2.0M | ||
| Q1 24 | $5.2M | $2.4M |
净利润AMSBGLC
| Q4 25 | $-631.0K | $-1.0M | ||
| Q3 25 | $-17.0K | $-709.0K | ||
| Q2 25 | $-280.0K | $-616.2K | ||
| Q1 25 | $-625.0K | $-623.3K | ||
| Q4 24 | $-1.3M | $-348.3K | ||
| Q3 24 | $-207.0K | $-1.3M | ||
| Q2 24 | $3.6M | $199.1K | ||
| Q1 24 | $119.0K | $-103.8K |
毛利率AMSBGLC
| Q4 25 | 11.7% | -0.8% | ||
| Q3 25 | 22.1% | 14.8% | ||
| Q2 25 | 23.1% | 16.3% | ||
| Q1 25 | 15.4% | 16.1% | ||
| Q4 24 | 35.3% | 12.3% | ||
| Q3 24 | 19.6% | 12.4% | ||
| Q2 24 | 35.0% | 14.6% | ||
| Q1 24 | 41.1% | 15.3% |
营业利润率AMSBGLC
| Q4 25 | -18.1% | -213.5% | ||
| Q3 25 | -4.8% | -27.6% | ||
| Q2 25 | -7.7% | -27.0% | ||
| Q1 25 | -21.3% | -28.9% | ||
| Q4 24 | -20.2% | -16.5% | ||
| Q3 24 | -12.7% | -50.9% | ||
| Q2 24 | -0.0% | 13.1% | ||
| Q1 24 | -1.6% | -3.3% |
净利率AMSBGLC
| Q4 25 | -8.2% | -214.2% | ||
| Q3 25 | -0.2% | -27.9% | ||
| Q2 25 | -4.0% | -27.3% | ||
| Q1 25 | -10.2% | -29.2% | ||
| Q4 24 | -14.6% | -13.8% | ||
| Q3 24 | -3.0% | -51.1% | ||
| Q2 24 | 51.0% | 10.1% | ||
| Q1 24 | 2.3% | -4.4% |
每股收益（稀释后）AMSBGLC
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $0.00 | $-0.40 | ||
| Q2 25 | $-0.04 | $-0.34 | ||
| Q1 25 | $-0.10 | $-0.04 | ||
| Q4 24 | $-0.21 | $0.55 | ||
| Q3 24 | $-0.03 | $-0.75 | ||
| Q2 24 | $0.55 | $0.11 | ||
| Q1 24 | $0.02 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $2.5M |
| 总债务越低越好 | $17.4M | — |
| 股东权益账面价值 | $24.0M | $8.6M |
| 总资产 | $55.5M | $9.3M |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资AMSBGLC
| Q4 25 | $3.5M | $2.5M | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $11.1M | — | ||
| Q1 25 | $11.2M | — | ||
| Q4 24 | $11.0M | $2.9M | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $14.2M | — | ||
| Q1 24 | $12.8M | — |
总债务AMSBGLC
| Q4 25 | $17.4M | — | ||
| Q3 25 | $18.2M | — | ||
| Q2 25 | $19.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | $20.4M | — | ||
| Q3 24 | $14.4M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $15.6M | — |
股东权益AMSBGLC
| Q4 25 | $24.0M | $8.6M | ||
| Q3 25 | $24.6M | $6.8M | ||
| Q2 25 | $24.5M | $7.5M | ||
| Q1 25 | $24.6M | $7.8M | ||
| Q4 24 | $25.2M | $8.3M | ||
| Q3 24 | $26.4M | $9.4M | ||
| Q2 24 | $26.5M | $9.5M | ||
| Q1 24 | $22.8M | $9.3M |
总资产AMSBGLC
| Q4 25 | $55.5M | $9.3M | ||
| Q3 25 | $59.6M | $7.6M | ||
| Q2 25 | $63.5M | $9.4M | ||
| Q1 25 | $63.3M | $9.5M | ||
| Q4 24 | $60.2M | $10.4M | ||
| Q3 24 | $63.3M | $11.0M | ||
| Q2 24 | $60.8M | $11.1M | ||
| Q1 24 | $50.1M | $11.2M |
负债/权益比AMSBGLC
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-704.0K | $961.1K |
| 自由现金流经营现金流 - 资本支出 | $-2.7M | $960.1K |
| 自由现金流率自由现金流/营收 | -34.8% | 198.5% |
| 资本支出强度资本支出/营收 | 25.7% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.5M | $-1.9M |
8季度趋势，按日历期对齐
经营现金流AMSBGLC
| Q4 25 | $-704.0K | $961.1K | ||
| Q3 25 | $1.7M | $-1.2M | ||
| Q2 25 | $-372.0K | $-737.9K | ||
| Q1 25 | $2.5M | $-824.1K | ||
| Q4 24 | $274.0K | $219.2K | ||
| Q3 24 | $472.0K | $-1.6M | ||
| Q2 24 | $1.3M | $-672.3K | ||
| Q1 24 | $-1.9M | $-37.2K |
自由现金流AMSBGLC
| Q4 25 | $-2.7M | $960.1K | ||
| Q3 25 | $-2.0M | $-1.2M | ||
| Q2 25 | $-2.3M | $-759.4K | ||
| Q1 25 | $-1.5M | $-833.1K | ||
| Q4 24 | $-4.4M | $215.2K | ||
| Q3 24 | $-407.0K | $-1.8M | ||
| Q2 24 | $70.0K | $-674.1K | ||
| Q1 24 | $-3.0M | $-59.1K |
自由现金流率AMSBGLC
| Q4 25 | -34.8% | 198.5% | ||
| Q3 25 | -28.3% | -48.9% | ||
| Q2 25 | -32.1% | -33.6% | ||
| Q1 25 | -24.7% | -39.0% | ||
| Q4 24 | -48.4% | 8.5% | ||
| Q3 24 | -5.8% | -68.5% | ||
| Q2 24 | 1.0% | -34.1% | ||
| Q1 24 | -58.4% | -2.5% |
资本支出强度AMSBGLC
| Q4 25 | 25.7% | 0.2% | ||
| Q3 25 | 51.6% | 0.2% | ||
| Q2 25 | 26.9% | 0.9% | ||
| Q1 25 | 65.7% | 0.4% | ||
| Q4 24 | 51.4% | 0.2% | ||
| Q3 24 | 12.6% | 7.6% | ||
| Q2 24 | 17.2% | 0.1% | ||
| Q1 24 | 22.7% | 0.9% |
现金转化率AMSBGLC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.36× | -3.38× | ||
| Q1 24 | -15.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMS
| Direct Patient Services | $4.0M | 51% |
| Rental Income From Medical Services | $2.7M | 35% |
| Pbrt Services | $1.2M | 15% |
BGLC
暂无分部数据
